Rocket Pharmaceuticals, Inc.

NasdaqGM:RCKT Stock Report

Market Cap: US$753.1m

Rocket Pharmaceuticals Future Growth

Future criteria checks 5/6

Rocket Pharmaceuticals is forecast to grow earnings and revenue by 61.3% and 54% per annum respectively. EPS is expected to grow by 58.7% per annum. Return on equity is forecast to be -38.4% in 3 years.

Key information

61.3%

Earnings growth rate

58.7%

EPS growth rate

Biotechs earnings growth24.0%
Revenue growth rate54.0%
Future return on equity-38.4%
Analyst coverage

Good

Last updated09 May 2025

Recent future growth updates

Recent updates

We're Keeping An Eye On Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Apr 02
We're Keeping An Eye On Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Rocket Pharma Is A Buy At These Prices With Promising Data

Feb 12

Rocket Pharmaceuticals: Not Bad Valuation But Reflexivity Risks Remain

Dec 02

Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?

Sep 23
Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?

Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review

Sep 15

Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix

Jun 28

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Jun 09
We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Apr 05

Rocket Pharmaceuticals' Promising Path In Gene Therapy

Mar 01

Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Nov 07
Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering

Oct 03

Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate

Aug 25

We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Jul 22
We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs

Jul 08

Rocket Pharma: Poised For Growth In The Rare Disease Space

Jun 30

Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside

Jan 30

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Nov 09
We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes

Oct 01

Earnings and Revenue Growth Forecasts

NasdaqGM:RCKT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20273803139-108
12/31/2026113-206-176-10612
12/31/20252-238-208-1378
3/31/2025N/A-258-213-209N/A
12/31/2024N/A-259-216-210N/A
9/30/2024N/A-258-202-192N/A
6/30/2024N/A-253-210-197N/A
3/31/2024N/A-249-210-194N/A
12/31/2023N/A-246-211-195N/A
9/30/2023N/A-253-236-222N/A
6/30/2023N/A-249-219-208N/A
3/31/2023N/A-237-206-196N/A
12/31/2022N/A-222-186-178N/A
9/30/2022N/A-199-160-153N/A
6/30/2022N/A-192-147-137N/A
3/31/2022N/A-172-145-136N/A
12/31/2021N/A-169-129-121N/A
9/30/2021N/A-186-122-103N/A
6/30/2021N/A-165-108-93N/A
3/31/2021N/A-155-92-77N/A
12/31/2020N/A-140-95-75N/A
9/30/2020N/A-99-98-81N/A
6/30/2020N/A-89-98-75N/A
3/31/2020N/A-82-99-71N/A
12/31/2019N/A-77-88-65N/A
9/30/2019N/A-85-81-66N/A
6/30/2019N/A-82-75-67N/A
3/31/2019N/A-79-60-58N/A
12/31/2018N/A-75N/A-54N/A
9/30/2018N/A-54N/A-39N/A
6/30/2018N/A-44N/A-31N/A
3/31/2018N/A-32N/A-24N/A
12/31/2017N/A-20N/A-16N/A
9/30/2017N/A-16N/A-12N/A
6/30/2017N/A-11N/A-9N/A
3/31/2017N/A-9N/A-8N/A
12/31/2016N/A-8N/A-6N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RCKT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).

Earnings vs Market: RCKT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RCKT is expected to become profitable in the next 3 years.

Revenue vs Market: RCKT's revenue (54% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: RCKT's revenue (54% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RCKT is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 08:07
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rocket Pharmaceuticals, Inc. is covered by 24 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Konstantinos BiliourisBMO Capital Markets Equity Research
Jason ZemanskyBofA Global Research
Whitney IjemCanaccord Genuity